Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in June 2011 on request of the sponsor.
On 23 February 2011, orphan designation (EU/3/10/838) was granted by the European Commission to Pharma Mar S.A. Sociedad Unipersonal, Spain, for plitidepsin for the treatment of post-essential thrombocythaemia myelofibrosis.
Treatment of post-essential thrombocythaemia myelofibrosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in June 2011 on request of the sponsor, before a marketing authorisation had been granted.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: